DDI Awards represent a critical early-stage doorway into the NF pre-clinical pipeline. The program will support projects that may have no preliminary data but which do have a sound rationale for testing candidate therapeutics in NF cell or mouse models.
The goal for these projects is to go on and secure larger grants from federal or private sources to continue progress.
Funding & Duration
Awards will provide up to US $40,000 (approx AUD $52,600) to fund in-vitro cell-based pre-clinical drug testing studies; or up to US $85,000 (approx. AUD $112,000) to fund in-vivo animal-based preclinical drug testing studies.
Applicant should have an MD, Ph.D. or equivalent and have full access to, or identified collaborators with, all required resources including all in vivo and in vitro models.
There are no citizenship requirements for this program. Applications are welcomed from all qualified individuals worldwide.
Applications are welcomed from both the academic and private sectors. Partnerships between the two are actively encouraged.
Submission Requirements & Due Date
- Applications must be submitted for internal review by 18 September 2017
- Please complete your RFR through ResearchMaster and when prompted to Select Fund Scheme use Fund Scheme code 9999 (Other)
- See also Submitting an Application to Research Services for Review